Colon-Otero G - Search Results

1

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.

Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, Brauer HA, Warren S, Danaher P, Colon-Otero G, Partridge AH, Carey LA, Hilbers F, Van Dooren V, Holmes E, Di Cosimo S, Werner O, Huober JB, Dueck AC, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson KL, Perez EA, Thompson EA. Chumsri S, et al. Among authors: colon otero g. NPJ Breast Cancer. 2022 May 24;8(1):68. doi: 10.1038/s41523-022-00430-0. NPJ Breast Cancer. 2022. PMID: 35610260 Free PMC article.

2

Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.

Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus RD, Vukov A, Li CY, Menke DM, Geyer SM, Alberts SR; North Central Cancer Treatment Group. Moreno-Aspitia A, et al. Cancer. 2006 Aug 15;107(4):767-72. doi: 10.1002/cncr.22047. Cancer. 2006. PMID: 16826578 Free article. Clinical Trial.

3

Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients.

Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Zubair AC, et al. Transfusion. 2008 Jun;48(6):1106-14. doi: 10.1111/j.1537-2995.2008.01651.x. Epub 2008 Feb 25. Transfusion. 2008. PMID: 18315528 Free PMC article.

4

Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population.

Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Chewar DM, Abaya R, Colon-Otero G, Perez EA. Palmieri FM, et al. Mayo Clin Proc. 2009 Apr;84(4):317-22. doi: 10.1016/S0025-6196(11)60539-9. Mayo Clin Proc. 2009. PMID: 19339648 Free PMC article.

5

Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups.

Patel TA, Colon-Otero G, Bueno Hume C, Copland JA 3rd, Perez EA. Patel TA, et al. Oncologist. 2010;15(5):466-75. doi: 10.1634/theoncologist.2010-0004. Epub 2010 Apr 28. Oncologist. 2010. PMID: 20427382 Free PMC article. Review.

6

Increased incidence of loco-regional recurrences among african american women with terminal stage breast cancer.

Colón-Otero G, King S, Smith V, Bieber C, Crook J, Solberg LA, Shannon R, Perez EA. Colón-Otero G, et al. Clin Med Oncol. 2008;2:547-50. doi: 10.4137/cmo.s988. Epub 2008 Nov 3. Clin Med Oncol. 2008. PMID: 21892330 Free PMC article.

7

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA. Cooper SJ, et al. Mol Cancer Ther. 2012 Oct;11(10):2105-15. doi: 10.1158/1535-7163.MCT-11-0873. Epub 2012 Jul 23. Mol Cancer Ther. 2012. PMID: 22826467 Free PMC article.

8

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. Moreno-Aspitia A, et al. Breast Cancer Res Treat. 2013 Apr;138(2):427-35. doi: 10.1007/s10549-013-2469-2. Epub 2013 Mar 12. Breast Cancer Res Treat. 2013. PMID: 23479422 Free PMC article. Clinical Trial.

9

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Perez EA, et al. J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20. J Clin Oncol. 2014. PMID: 25332249 Free PMC article. Clinical Trial.

10

Erratum: Dual HER2 blockade: preclinical and clinical data.

Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Patel TA, et al. Breast Cancer Res. 2014 Nov 6;16(6):468. doi: 10.1186/s13058-014-0468-9. Breast Cancer Res. 2014. PMID: 25927825 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page